Manganese sulfate

151.00100

150.89000

233-342-6

IGA15S9H40

DTXSID9044160

White orthorhombic crystals

2833299090

88.64000

-0.25720

Gray to pink crystalline powder.

3.25 g/cm³

700 °C

850ºC

Slightly soluble in methanol.

Store in a tightly closed container in a cool, dry place, away from heat and direct sunlight.

Mono-, tetra-, penta-, and hepta- hydrates are pink.

UN 1760

R48/20/22

S22

Xn; N

Stable under normal conditions of use.

P260, P264, P270, P273, P280, P301+P312, P305+P351+P338, P310, P314, P330, P391, P501

H302

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Manganese sulfate in nutrients and/or dietary supplements is generally recognized as safe when used in accordance with good manufacturing or feeding practices.|Substance added directly to human food affirmed as generally recognized as safe (GRAS).|Trace minerals added to animal feeds. These substances added to animal feeds as nutritional dietary supplements are generally recognized as safe when added at levels consistent with good feeding practice. Element: Manganese; Source compound: manganese sulfate. (All substances listed may be in anhydrous or hydrated form.)

USEPA; Locating and Estimating Air Emissions from Sources of Manganese (1985) EPA-450/4-84-007h|USEPA; Health Assessment Document: Manganese (1984) EPA-600/8-83-013F|WHO; Environ Health Criteria: Manganese (1981)|WHO; Environ Health Criteria: Manganese-Executive Summary (1981)|For more Special Reports (Complete) data for MANGANESE SULFATE (6 total), please visit the HSDB record page.

|Warning|H373 **: Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]|P260, P273, P314, P391, and P501|Danger|H318 (24.96%): Causes serious eye damage [Danger Serious eye damage/eye irritation]|P260, P273, P280, P305+P351+P338, P310, P314, P391, and P501|Aggregated GHS information provided by 713 companies from 35 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H302: Harmful if swallowed [Warning Acute toxicity, oral]|P260, P264, P270, P273, P280, P301+P312, P305+P351+P338, P310, P314, P330, P391, and P501|P201, P202, P260, P264, P270, P273, P281, P301+P312, P308+P313, P314, P330, P405, and P501|P201, P202, P260, P264, P270, P281, P301+P312, P307+P311, P308+P313, P314, P321, P330, P405, and P501

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants.

Permissible Exposure Limit: Table Z-1 Ceiling value: 5 mg/cu m. /Manganese cmpd (as Mn)/

Recommended Exposure Limit: 10 Hr Time-Weighted Avg: 1 mg/cu m. /Manganese compounds and fume (as Mn)/|Recommended Exposure Limit: 15 Min Short-Term Exposure Limit: 3 mg/cu m. /Manganese compounds and fume (as Mn)/

Listed as a hazardous air pollutant (HAP) generally known or suspected to cause serious health problems. The Clean Air Act, as amended in 1990, directs EPA to set standards requiring major sources to sharply reduce routine emissions of toxic pollutants. EPA is required to establish and phase in specific performance based standards for all air emission sources that emit one or more of the listed pollutants. Manganese sulfate is included on this list.|... Substances for which a Federal Register notice has been published that included consideration of the serious health effects, including cancer, form ambient air exposure to the substance. Manganese (50 FR 32627; Aug. 13, 1985) is included on this list. /Manganese/

The present study was designed primarily to investigate the biliary excretion of organic bile constituents following administration of the manganese-bilirubin combination. Experiments in hyperbilirubinemic Gunn rats were also performed to determine whether the unconjugated or the conjugated form of bilirubin is involved in this cholestatic interaction. Male Sprague-Dawley rats and male homozygous Gunn rats were given the following (iv.): (a) manganese (4.5 mg per kg); (b) unconjugated bilirubin (25 mg per kg); (c) bilirubin ditaurate (38 mg per kg); (d) manganese- unconjugated bilirubin, or (e) manganese-bilirubin ditaurate. Bile flow was measured and bile was analyzed for manganese, total bilirubin, bile salts, cholesterol and phospholipid content. The results show that: (i) manganese- unconjugated bilirubin treatment caused about manganese unconjugated bilirubin treatment caused about a 50% reduction in bile flow in Sprague Dawley rats, whereas in Gunn rats the manganese bilirubin ditaurate treatment resulted in about a 75% reduction, and (ii) in both strains, bile salt excretion was not appreciably modified during the cholestatic phase, as biliary bile salt concentration increased. The results suggest that although that although important differences regarding the form of bilirubin apparently exist, unconjugated bilirubin could be implicated in the cholestatic interaction in both strains of rats. Manganese bilirubin induced cholestasis is not related to a defect in bile salt excretion. The latter supports our contention that diminished canalicular membrane permeability to water is likely to be a key factor in this form of experimental cholestasis.|EFFECTS OF PARENTERAL METAL SUPPLEMENTS ON SALICYLATE TERATOGENICITY WAS STUDIED IN RATS. MANGANOUS SULFATE (10 MG/KG) SIGNIFICANTLY ENHANCED TERATOGENIC EFFECTS OF SODIUM SALICYLATE.|Manganese-bilirubin (Mn-BR)-induced cholestasis in rats is associated with altered lipid composition of various hepatic subcellular fractions. Increased bile canalicular (BCM) cholesterol content in Mn-BR cholestasis & the intracellular source of the accumulating cholesterol were investigated. To label the total hepatic cholesterol pool, male Sprague-Dawley rats were given ip 3H-cholesterol, followed 18 hr later by 2-14C-mevalonic acid (a precursor of cholesterol synthesis). To induce cholestasis, manganese (Mn, 4.5 mg/kg) & bilirubin (BR, 25 mg/kg) were injected iv; animals were killed 30 min after BR injection; canalicular and sinusoidal membranes, microsomes, mitochondria, & cytosol were isolated. Total cholesterol content of each fraction was determined by spectrophotometric techniques as well as radiolabeled techniques. In Mn-BR cholestasis, the total cholesterol concns of BCM & cytosol were significantly increased. Also, the contribution of 14C-labeled cholesterol (newly synthesized cholesterol) was enhanced in all isolated cellular fractions. The results are consistent with the hypothesis that accumulation of newly synthesized cholesterol in BCM is involved in Mn-BR cholestasis. An enhanced rate of synthesis of cholesterol, however, does not appear to be the causal event, as the activity of HMG-CoA reductase (rate-limiting enzyme in cholesterol synthesis), assessed in vitro, was decreased following Mn-BR treatment. Treatment with the Mn-BR combination may affect other aspects of intracellular cholesterol dynamics.

LD100 Mouse oral 305 mg/kg /From table/|LD50 Mouse intraperitoneal 64 mg/kg /From table/|LD100 Mouse subcutaneous 146 mg/kg /From table/

... Toxicology and carcinogenesis studies were conducted by administering manganese (II) sulfate monohydrate (97% pure) in feed to groups of male and female F344/N rats and B6C3F1 mice for ... 2 yr. ... 2 YEAR STUDY IN RATS: Groups of 70 male and 70 female rats were fed diets containing 0, 1,500, 5,000, or 15,000 ppm manganese (II) sulfate monohydrate. Based on average daily feed consumption, these doses resulted in the daily ingestion of 60, 200, or 615 mg/kg body weight (males) or 70, 230, or 715 mg/kg (females). ... 2 YEAR STUDY IN MICE: Groups of 70 male and 70 female mice received diets containing 0, 1,500, 5,000, or 15,000 ppm manganese (II) sulfate monohydrate. These levels resulted in an average daily ingestion of 160, 540, or 1,800 mg/kg body weight (males) or 200, 700, or 2,250 mg/kg (females). ... CONCLUSIONS: Under the conditions of these 2-year feed studies, there was no evidence of carcinogenic activity of manganese (II) sulfate monohydrate in male or female F344/N rats receiving 1,500, 5,000, or 15,000 ppm. There was equivocal evidence of carcinogenic activity of manganese (II) sulfate monohydrate in male and female B6C3FI mice, based on the marginally increased incidences of thyroid gland follicular cell adenoma and the significantly increased incidences of follicular cell hyperplasia. /Mangansese sulfate monohydrate/

MEDICATION (VET): To prevent or treat manganese deficiency.|MEDICATION (VET): NUTRITIONAL FACTOR (ESSENTIAL TRACE ELEMENT IN ALL ANIMALS); PREVENTION OF PEROSIS IN POULTRY.|MEDICATION: NUTRIENT &/OR DIETARY SUPPLEMENTAL FOOD ADDITIVE

WHEN LARGE DOSES OF MANGANESE SULFATE ARE INJECTED IV EXCRETION IS ALMOST EXCLUSIVELY IN FECES ... .|/Manganese sulfate/ is poorly absorbed through lung and gut.

TRACE IMPURITIES: Zinc, nitrogen and cobalt

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . /Manganese and related compounds/|Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious or in severe respiratory distress. Monitor cardiac rhythm and treat arrhythmias if necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Consider vasopressors for hypotension with a normal fluid volume. Watch for signs of fluid overload ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Manganese and related compounds/

manganese sulfate

CHEMICAL PROFILE: Manganese Sulfate. Fertilizer, 60%; livestock nutrients, 30%; miscellaneous industrial uses, 10%.

32% manganese sulfate monohydrate, maxi-granular, mini-granular and powder /Techmangam/|Grades: technical; CP /chemically pure/; fertilizer; feed|The commercial product is the monohydrate (technical grade).|Commercial grades contain 29.5-32.0% Mn corresponding to the mono- or dihydrate.|For more Formulations/Preparations (Complete) data for MANGANESE SULFATE (7 total), please visit the HSDB record page.

Agriculture, forestry, fishing and hunting|Sulfuric acid, manganese(2+) salt (1:1): ACTIVE|Article of commerce is usually a mixture of tetra- and pentahydrates.

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients